Production (Stage)
Monopar Therapeutics Inc.
MNPR
$37.11
-$0.905-2.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 27.60% | -2.33% | -8.81% | -1.47% | 2.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 119.94% | 83.01% | -28.79% | -26.35% | -24.28% |
| Operating Income | -119.94% | -83.01% | 28.79% | 26.35% | 24.28% |
| Income Before Tax | -117.78% | -85.50% | 31.73% | 28.26% | 27.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -117.78% | -85.50% | 31.73% | 28.26% | 27.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -117.78% | -85.50% | 31.73% | 28.26% | 27.49% |
| EBIT | -119.94% | -83.01% | 28.79% | 26.35% | 24.28% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -31.00% | -17.72% | 44.09% | 39.31% | 35.30% |
| Normalized Basic EPS | -30.99% | -17.73% | 44.08% | 39.31% | 35.30% |
| EPS Diluted | -31.00% | -17.72% | 44.21% | 39.58% | 35.57% |
| Normalized Diluted EPS | -30.99% | -17.73% | 44.08% | 39.31% | 35.30% |
| Average Basic Shares Outstanding | 62.60% | 36.76% | 22.82% | 19.35% | 13.21% |
| Average Diluted Shares Outstanding | 62.60% | 36.76% | 22.82% | 19.35% | 13.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |